Emily Bodnar’s score is based within the anticipation of sizeable milestones for Agenus in the coming yr, notably the likely submitting of the Biologics License Software (BLA) for his or her guide drug prospect, botensilimab (bot). Agenus has dosed around 900 patients with bot across numerous sound tumors, exhibiting a determination to considerab